Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab

PURPOSE: Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of I...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Fayad, Luis, Offner, Fritz, Smith, Mitchell R., Verhoef, Gregor, Johnson, Peter, Kaufman, Jonathan L., Rohatiner, Ama, Advani, Anjali, Foran, James, Hess, Georg, Coiffier, Bertrand, Czuczman, Myron, Giné, Eva, Durrant, Simon, Kneissl, Michelle, Luu, Kenneth T., Hua, Steven Y., Boni, Joseph, Vandendries, Erik, Dang, Nam H.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2013
Teme:
ORIGINAL REPORTS
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878046/
https://ncbi.nlm.nih.gov/pubmed/23295790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.7211
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki